Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.56 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.54 |
| ▸ | SCD | O00767 | 11/20 | 0.50 |
| ▸ | SCD5 | Q86SK9 | 8/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27379736 | 0.88 | GRM2 (0.55) | GRM2KLKB1SMN1; SMN2HPGDLMNA | |
| SCHEMBL28587535 | 0.87 | SMN1; SMN2 (0.50) | GRM2KLKB1SMN1; SMN2HPGDLMNA | |
| SCHEMBL30119622 | 0.87 | SMN1; SMN2 (0.50) | GRM2KLKB1SMN1; SMN2HPGDLMNA | |
| SCHEMBL1546755 | 0.86 | GRM2 (0.50) | GRM2SCD5SMN1; SMN2HPGDADORA2A | |
| SCHEMBL3093449 | 0.85 | GRM2 (0.63) | GRM2KLKB1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL553848 | 0.85 | ALDH1A1 (0.60) | GRM2KLKB1SMN1; SMN2LMNATDP1 | |
| SCHEMBL4771423 | 0.85 | MEN1 (0.62) | GRM2KLKB1SMN1; SMN2HPGDLMNA | |
| SCHEMBL2824923 | 0.84 | GRM2 (0.57) | GRM2KLKB1SCDSMN1; SMN2HPGD | |
| SCHEMBL30755417 | 0.84 | GRM2 (0.57) | GRM2KLKB1SCDSMN1; SMN2HPGD | |
| SCHEMBL31591067 | 0.83 | KLKB1 (0.58) | GRM2KLKB1SMN1; SMN2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1678181-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005042534-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | GRM2 625/4885KLKB1 2283/4885SCD 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.